FMC-242 is a potentially best-in-class covalent allosteric inhibitor that breaks the interaction between PI3Kα and RAS, ...
Researchers found that 160 milligrams of daily aspirin significantly lowered cancer recurrence risk for colorectal patients ...
Identifying Oncology Clinical Trial Candidates Using Artificial Intelligence Predictions of Treatment Change: A Pilot Implementation Study Pretreatment tumor was evaluated from operable TNBC patients ...
Addressing Administrative and Regulatory Burden in Cancer Clinical Trials: Summary of a Stakeholder Survey and Workshop Hosted by the American Society of Clinical Oncology and the Association of ...
Celcuity Inc. surges to a $2B valuation on strong phase 3 data for gedatolisib in hormone-positive breast cancer. Read why ...
A groundbreaking international study has found that imlunestrant plus abemaciclib significantly improved progression-free survival (PFS) versus imlunestrant monotherapy in patients with estrogen ...
Imlunestrant monotherapy significantly improved PFS compared with standard endocrine therapy, with a median PFS of 5.5 months vs 3.8 months. The combination of imlunestrant and abemaciclib further ...
An international research team has identified a previously unknown mechanism by which the breast cancer drug tamoxifen can increase the risk of secondary tumors in the uterus. The study shows that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback